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Structural basis of DNA gyrase inhibition by
antibacterial QPT-1, anticancer drug etoposide
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New antibacterials are needed to tackle antibiotic-resistant bacteria. Type IIA topoisomerases
(topo2As), the targets of ﬂuoroquinolones, regulate DNA topology by creating transient
double-strand DNA breaks. Here we report the ﬁrst co-crystal structures of the antibacterial
QPT-1 and the anticancer drug etoposide with Staphylococcus aureus DNA gyrase, showing
binding at the same sites in the cleaved DNA as the ﬂuoroquinolone moxiﬂoxacin. Unlike
moxiﬂoxacin, QPT-1 and etoposide interact with conserved GyrB TOPRIM residues
rationalizing why QPT-1 can overcome ﬂuoroquinolone resistance. Our data show etoposide’s
antibacterial activity is due to DNA gyrase inhibition and suggests other anticancer agents act
similarly. Analysis of multiple DNA gyrase co-crystal structures, including asymmetric
cleavage complexes, led to a ‘pair of swing-doors’ hypothesis in which the movement of one
DNA segment regulates cleavage and religation of the second DNA duplex. This mechanism
can explain QPT-1’s bacterial speciﬁcity. Structure-based strategies for developing topo2A
antibacterials are suggested.
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F
luoroquinolone antibacterials and several classes of
anti-cancer agents function by generation of ‘poison’
complexes between type IIA topoisomerases (topo2As)
and DNA1–5. Structures of such ‘poison’ complexes such as the
ﬂuoroquinolone moxiﬂoxacin with DNA and a bacterial topo2A6,
and of the anticancer drug etoposide with DNA and human
Top2b7, showed the drugs bound in the DNA at the cleavage sites
making speciﬁc interactions with the proteins and inhibiting
DNA religation (Fig. 1). Two new classes of antibacterials that
target the DNA gate of bacterial topo2As are currently in phase II
clinical trials: gepotidacin (pronounced Jepo- tide- a- cin,
formerly GSK2140944 (ref. 8)), a novel bacterial topoisomerase
inhibitor (NBTI) related to GSK299423 (ref. 9), and AZD0914
(refs 10–13), a derivative of QPT-1 (quinoline pyrimidine trione-
1)14 (Supplementary Fig. 1).
Bacteria have two well-conserved topo2As, DNA gyrase and
topoisomerase IV (topo IV), which allow for dual targeting by
antibacterials, affording reduced spontaneous resistance15. DNA
gyrase consists of two subunits, GyrA and GyrB, and functions as
an A2B2 tetramer, as does topo IV, which consists of ParC and
ParE subunits. Topo2As regulate DNA topology16 by creating a
four base-pair-staggered double-stranded break (DSB) in one
DNA duplex, passing another DNA duplex through this break
and then resealing the break (Fig. 1). The two catalytic gates
of the enzyme, the amino-terminal ATP gate and the central
DNA-cleavage gate, are each targeted by multiple antibacterial
agents5. No inhibitors of the ATPase domain (ATP gate) are
currently in clinical use; in contrast, the highly successful
quinolone/ﬂuoroquinolone antibacterials1 have been in clinical
use for nearly 50 years, with new members of this class currently
in development5. The primary interaction of ﬂuoroquinolones
with the protein is via a water–metal ion bridge6,17,18 to two
conserved residues on GyrA (Ser84 and Glu88 in S. aureus
GyrA); these two residues are the most commonly mutated in
clinical isolates resistant to ﬂuoroquinolones1,19. Residues
equivalent to Ser84 and Glu88 are conserved in bacterial
topo2As, but the corresponding residues in mammalian
topo2As are different, accounting for much of the speciﬁcity of
ﬂuoroquinolones1,17. Eukaryotic topo2As (such as human Top2a
and Top2b, and yeast Topo II) function as homodimers, with
regions equivalent to GyrB and GyrA encoded at the N- and
carboxy-terminal ends, respectively, of a single polypeptide.
Human topo2As are the targets of several anticancer
agents2 including doxorubicin, amascrine, mitoxantrone20 and
etoposide, with the latter in clinical use for over 30 years7. A high-
resolution structure of etoposide with hTop2b7 showed the drug
bound in the cleaved DNA making interactions with Gln778
and Met782.
QPT-1 (Fig. 1) represents a novel class of antibacterial
compounds targeting bacterial DNA gyrase and topo IV, with a
broad spectrum of antimicrobial activity and good selectivity with
respect to human Top2a14,21. The class is reported to overcome
target-mediated ﬂuoroquinolone resistance and this has attracted
signiﬁcant industry effort, with several hundred analogues
reported in the scientiﬁc and patent literature from multiple
companies5. However, the structural and mechanistic basis of
action of this class and the mechanism by which it overcomes
ﬂuoroquinolone cross-resistance have not previously been
reported.
In this study we show that etoposide and other anticancer
agents also have a surprising level of activity against a range of
bacteria, and that this is due to inhibition of DNA gyrase. We also
report the ﬁrst co-crystal structures of DNA-cleavage complexes
for QPT-1, as well as co-crystal structures for etoposide and
moxiﬂoxacin. Our structures include the ﬁrst asymmetric topo2A
DNA-cleavage complexes, showing that inhibitors can stabilize an
asymmetric conformation of the DNA gate. Out of the diversity
of inhibitors discussed, important generalizable themes and
insights emerge for overcoming ﬂuoroquinolone resistance using
new chemistries and binding strategies, including targeting the
GyrB TOPRIM domain.
Results
Structures of S. aureus gyrase DNA-cleavage complexes. As part
of a structure-based approach to develop novel bacterial topo2A
pharmacophores, we co-crystallized and determined structures22
of DNA-cleavage complexes of the S. aureus B27-A56(GKdel)
fusion truncate (gyraseCORE) with QPT-1, etoposide and
moxiﬂoxacin (Figs 1–3, Table 1, Supplementary Fig. 2 and
Supplementary Table 1). In DNA-cleavage assays, QPT-1 and
moxiﬂoxacin stabilized DSBs with S. aureus DNA gyrase, whereas
etoposide stabilized both single-stranded breaks (SSB) and DSBs
(Fig. 2e,f and Table 2). Compound-stabilized DNA-cleavage
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Figure 1 | Schematics of S. aureus DNA gyrase cleavage complexes with
inhibitors. Chemical structures of (a) QPT-1, (b) etoposide and (c)
moxiﬂoxacin (with associated magnesium ion). (d) Schematic of structure
of S. aureus gyraseCORE DNA-cleavage complex containing two inhibitors (I)
binding in the cleaved DNA-blocking re-ligation. By convention, nucleotides
are numbered relative to the cleavage sites. (e) DNA gyrase consists of two
subunits: GyrB and GyrA. The S. aureus gyraseCORE construct used to
determine crystal structures reported in this study is a fusion of the
C-terminal TOPRIM (TOP) domain of GyrB with the N-terminal winged
helical domain (WHD), tower (TOW) and exit gate (EX) domains from
GyrA. The small Greek Key (GK) domain has been deleted9. (f) Schematic
of DNA gyrase showing how the gate DNA (G-DNA) is cleaved to allow
passage of the transport DNA (T-DNA), to regulate DNA topology.
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activities of the S. aureus gyraseCORE protein were comparable to
that of the wild-type protein (Supplementary Figs 3 and 4),
indicating the gyraseCORE truncate used in crystal studies was
functionally active.
All DNA-cleavage complex structures solved with QPT-1 and
moxiﬂoxacin contain two inhibitor molecules bound (Fig. 2 for
structures of complexes). With etoposide and moxiﬂoxacin, we
solved 2.80 and 2.95Å DNA-cleavage complex structures in a P21
unit cell with two complexes in the asymmetric unit (Table 1).
With QPT-1, in addition to solving a 3.15-Å structure in this P21
cell, we also solved a 2.50-Å QPT-1 structure in a P61 cell with
one complex in the asymmetric unit; the three QPT-1 complexes
were similar but not identical (see bottom line of Table 1
(for nomenclature) and below). In all the cleavage complexes
reported here, there was clear density for compounds at both
cleavage sites (Supplementary Fig. 2) and for the phosphotyrosine
bond formed between Tyr123/Tyr123’ of GyrA and the DNA
(residues with a ‘ sufﬁx are from the second subunit in the dimer).
In addition to the S. aureus cleavage complexes described, we
also solved a 2.45-Å structure with a single etoposide bound
(Fig. 2d and Supplementary Fig. 2k). The DNA used for this
structure was doubly nicked, with artiﬁcial breaks in the DNA
backbone at both cleavage sites. We further solved a 2.65-Å
binary complex (Table 1) with this DNA (without compound).
The basic binding modes for the three inhibitors are shown in
Fig. 3. Small variations in the binding modes for the same
compound in different complexes were observed (see below). In
the 2.95-Å S. aureus moxiﬂoxacin structure (Fig. 3d) the critical
interactions via the water–ion bridge18 with GyrA Ser84
and Glu88 are similar to those we described with a
Gram-negative topo IV6. The binding mode for etoposide in S.
aureus (Fig. 3c) is similar to that observed in the 2.1 Å human
topo2b complex7, which has two etoposide molecules bound.
QPT-1 binding is at the same site as moxiﬂoxacin. The co-
crystal structures with QPT-1 are novel and demonstrate for the
ﬁrst time that the functional inhibition of topo2As by QPT-1 is
similar to that of ﬂuoroquinolones, despite a very different
chemical structure, supporting the biochemical data in which
QPT-1 induces double-strand cleavage of DNA mediated by
DNA gyrase (Fig. 2a,e and Supplementary Fig. 2). Similar to the
ﬂuoroquinolones, QPT-1 is bound between the þ 1 and 1 bases
at the DNA cleavage site inhibiting DNA re-ligation. This
establishes that the clinically validated inhibition mechanism of
the ﬂuoroquinolones is achievable with very different interactions
from a completely different chemotype (Fig. 3a,d). QPT-1 is
bound in overlapping space with the ﬂuoroquinolones but the
e
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Figure 2 | S. aureus gyrase DNA-cleavage activity and crystal structures with three different inhibitors. (a) The structure of the 2.5Å ba_ba’2QPT
complex viewed down the twofold axis. QPT-1 (red space ﬁll) with gyrasecore (grey/green Ca trace) and cleaved DNA (backbone trace, orange; sticks,
carbons grey/green; oxygens, red; nitrogens, blue; phosphorus, orange) with two QPT-1 molecules bound. The three structural domains that make up the
DNA gate are labelled. It is noteworthy that the WHD (winged helical domain) is underneath the DNA in this view. (b) BA_BA’2–moxi complex of
moxiﬂoxacin (2.95Å; orange space ﬁll) with gyrasecore and DNA with two moxiﬂoxacin molecules bound. (c) BA_BA’2–etop complex of etoposide (2.8Å;
blue space ﬁll) with gyrasecore and DNA with two etoposide molecules bound. It is noteworthy that this complex is asymmetric, with the labelled Tower and
TOPRIM domains further apart than in other complexes shown (double arrow). (d) ba_ba’1–etop complex of etoposide (2.45Å; blue space ﬁll) with
gyrasecore and doubly nicked DNA, which has only one etoposide bound. Apart from the compound, the complex is C2 symmetric. (e) DNA-cleavage assay
showing moxiﬂoxacin and QPT-1 stabilize DSB with S. aureus DNA gyrase, whereas etoposide stabilizes both SSB and DSB. Each compound (100mM) was
incubated with supercoiled pBR322 and full-length S. aureus gyrase as described in Methods. (f) The etoposide-stabilized SSB and DSB persist over a wide
range of etoposide concentrations with S. aureus DNA gyrase.
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binding mode is strikingly different (Fig. 3). QPT-1 interacts with
residues in the TOPRIM domain of GyrB, with the barbituric acid
moiety of QPT-1 (Supplementary Fig. 1) packing under Arg458
and making a hydrogen bond to the main-chain N–H of Asp437
(Fig. 3a), and quite a close interaction with the main-chain CH2
of Gly436 (Fig. 4). QPT-1 also makes an indirect hydrogen bond
via a water molecule to the side chain of Asp437. The interaction
of QPT-1 with Asp437 somewhat resembles that made by the
central hydroxyl of etoposide (Fig. 3a,c inserts and
Supplementary Fig. 2). Etoposide-resistant strains of S. aureus
with a D437N or D437A mutation (see below and Table 2b) are
also resistant to QPT-1. Arg458 and Asp437 are from two
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Figure 3 | Binding sites for QPT-1, etoposide and moxiﬂoxacin in S. aureus DNA gyrase complexes. (a) QPT-1 structure (2.5Å) with S. aureus
gyraseCORE. The central oxygen of the barbituric acid moiety of QPT-1 (pink carbons) interacts with the main-chain N–H of Asp437 of GyrB (dotted black
lines). Water molecules (small red spheres) mediate interactions from the barbituric acid nitrogens of QPT-1 to the protein. DNA shown in green or black
carbons. The second GyrB/A subunits are labelled as prime. A different view of the Asp437 interaction of GyrB with barbituric acid of QPT-1 is shown in the
inner panel. (b) Schematic showing how QPT-1 binds in the cleaved DNA and interacts with GyrB via its barbituric acid moiety (arrowhead). The insert
panel shows the DNA gate opening. (c) Etoposide structure (2.8Å) with S. aureus gyraseCORE. It is noteworthy that the central oxygen of the dimethoxy
phenol group of etoposide (blue carbons) interacts with both the side-chain and main-chain N–H of Asp437 of GyrB. A different view of the Asp437
interaction with the dimethoxy phenol of etoposide is shown in the inner panel. (d) Moxiﬂoxacin structure (2.95Å) with S. aureus gyraseCORE. Moxiﬂoxacin
(orange carbons) interacts with Ser84 and Glu88 of GyrA via the magnesium–water ion bridge (dotted orange lines). In all structures shown, a
phosphotyrosine linkage exists between Tyr123 of GyrA and DNA (G1 nucleotide is shown as black, light sticks so that compound is not hidden).
Table 1 | Summary of six co-crystal structures.
QPT-1-2.5 QPT-1-3.15 Etop-2.8 Etop-2.45 Moxi-2.95 Binary
PDB CODE 5CDM 5CDO 5CDN 5CDP 5CDQ 5CDR
Compound QPT-1 QPT-1 Etoposide Etoposide Moxiﬂoxacin None
S. aureus gyrasecore protein Wild type Wild type Wild type GyrA Y123F Wild type GyrA Y123F
Cleavage complex* Yes Yes Yes No Yes No
DNA 20–447T 20–447T 20–447 20–12p-8 20–448T 20–12p-8
Space group P61 P21 P21 P61 P21 P61
Resolution (Å) 2.50 3.15 2.80 2.45 2.95 2.65
No. of compounds bound
per complex
2 2 2 1 2 0
No. of complexes in AU 1 2 2 1 2 1
Names of complexes in AUw ba_ba’2–QPT BA_BA’2–QPT
BA_BA’2–QPT
BA_BA’2–etop
BA_BA’2–etop
ba_ba’1–etop BA_BA’2–moxi
BA_BA’2–moxi
ba_ba’
AU, asymmetric unit; Etop, etoposide; Moxi, moxiﬂoxacin; QPT-1, quinoline pyrimidine trione-1.
See Supplementary Table 1 and Srikannathasan et al.22 for crystallographic details.
*The four cleavage complexes in the Table are all double-strand cleaved with a covalent phosphotyrosine bond linking the cleaved DNA to the protein (Y123). Crystallization with DNAs, with artiﬁcial
nicks in the DNA at both cleavage sites, more readily gives crystals; two of the complexes in the Table have nicked DNA, these are not cleavage complexes.
wDNA complexes were named with BA or ba representing one covalently fused B27-A56 gyraseCORE subunit and BA’ or ba’ the second subunit in the dimer. In the space group P21, the second complex is
distinguished from the ﬁrst by being in italics. The number of molecules and the name of the inhibitor bound in each complex are indicated in sufﬁx. Hence, the two QPT-1 cleaved complexes in the P21
cells are identiﬁed as BA_BA’2–QPT and BA_BA’ 2–QPT, and the one in the P61 cell as ba_ba’
2–QPT.
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Table 2 | Target potencies and antibacterial activities of inhibitors.
a CC50 or IVR IC50 (lM)*
QPT-1 Etoposide Moxiﬂoxacin
DNA cleavage
S. aureus DNA gyrasew 8.8 107 2.5z
Human Top2a 4800 21 4800
E. coli DNA gyrase 8.6 113 0.6z
E. coli gyrase-dependent IVR assay 0.34 4.3 0.17
b MIC (lgml1)
QPT-1 Etoposide Moxiﬂoxacin
S. aureus RN4220 0.5 64 0.063
S. aureus RN4220 GyrB D437N 4 128 0.063
S. aureus RN4220 GyrB D437A 2 256 0.063
S. pneumoniae 1629 — 2 0.031
S. pneumoniae 1629 GyrB R447C — 16 0.094
S. pneumoniae 1629 GyrB DL407–S410 — 16 0.047
E. coli 7623 8 4256 r0.016
E. coli 7623 DtolC 0.063 0.75 r0.016
IC50, half-maximal inhibitory concentration; IVR, in vitro DNA replication; MIC, minimum inhibitory concentration; QPT-1, quinoline pyrimidine trione-1; ‘—’, not measured.
(a) Activity in topoisomerase biochemical assays.
(b) Antimicrobial susceptibility against S. aureus, S. pneumoniae and E. coli strains.
See Supplementary Tables 3–6 for a full set of enzyme activity and MIC data.
*CC50 is deﬁned as amount of compound that causes half-maximal induction of linear DNA (double-stranded DNA breaks). IC50 is the amount of compound required to inhibit 50% of maximal DNA
replication activity. Values are averages of at least two independent studies.
wFull-length, wild-type form of S. aureus DNA gyrase protein.
zDNA cleavage data from Black et al.61.
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NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10048 ARTICLE
NATURE COMMUNICATIONS | 6:10048 | DOI: 10.1038/ncomms10048 |www.nature.com/naturecommunications 5
sequence motifs, PLRGK and EGDSA, which are conserved in
topo2As from bacteria to man (Supplementary Fig. 5) and a
similar interaction is observed in the etoposide-human Top2b
complex7. This sequence conservation may explain the cross-
activity of etoposide between bacteria and man but does not
readily explain the high bacterial selectivity of QPT-1 against
human Top2a (Table 2 and Supplementary Fig. 3).
The three different QPT-1 cleavage complexes have the
DNA gate closed in different ways (Fig. 4). These complexes
(ba_ba’2–QPT, BA_BA’2–QPT and BA_BA’ 2QPT; see Table 1)
come from the 2.5- and 3.15-Å QPT-1 co-crystal structures,
which were obtained under the same crystallization conditions22.
When the QPT-1-binding sites are compared (Fig. 4a and
Supplementary Fig. 6), the largest difference is seen in the relative
position of the G1 nucleotide, which is covalently attached to the
catalytic tyrosine from the opposing subunit (Fig. 3b). One
possible explanation for this spatial diversity may be the range of
tautomeric forms that the barbituric acid moiety of QPT-1 can
adopt as the DNA gate moves at the dimer interface (Fig. 4,
Supplementary Fig. 6 and Supplementary Table 2). Barbituric
acid23 and its derivatives24 are known to crystallize in several
different keto or enol tautomeric forms, stabilized by hydrogen
bonding in different crystal lattices24. In docking experiments,
eight tautomers of QPT-1 were evaluated in the two binding sites
of each QPT-1 complex and tautomers were tentatively assigned
to the different QPT-1-binding sites as described in Methods. As
the central keto oxygen of the barbituric acid moiety of QPT-1
points between the NH of Asp437 and the CH2 of Gly436 of
GyrB, this oxygen is unlikely to be protonated in any of the QPT-
1-binding sites. In contrast, the other two oxygens on the
barbituric acid were modelled as either protonated enol groups
(tautomers 6 and 4 in Fig. 4d,e) or unprotonated keto groups
(tautomers 1 and 4 in Fig. 4c,e). These two oxygens point towards
the p-electrons of the Gþ 1 and C1 nucleotide bases25. The
tertiary ‘anilino’ nitrogen atom in the central ring of QPT-1 can
also adopt different forms. In our structures, it is modelled in a
near-planar sp2 conﬁguration in ﬁve of the six QPT-1-binding
sites, but in the sixth is modelled in a more tetrahedral sp3
conﬁguration, accepting an internal hydrogen bond from a
neighbouring OH group (tautomer 6 in Fig. 4d and
Supplementary Table 2). The conformational ﬂexibility of
QPT-1, and its ability to adopt different tautomeric states, may
allow QPT-1 to maintain favourable interactions with its binding
site as the two subunits at the DNA gate move relatively to each
other and the size and shape of the QPT-1-binding pocket
changes.
AZD0914 is a compound related to QPT-1 (refs 11,26,27 and
Supplementary Fig. 1) that is currently in a phase II clinical trial
for the treatment of Neisseria gonorrhoeae10,12,13. We built a
model (see Methods) of AZD0914 in a DNA-cleavage complex
with N. gonorrhoeae DNA gyrase, based on the 2.5-Å QPT-1
crystal structure with S. aureus gyrase. Two residues, GyrB
Asp429 and Lys450, which pack against AZD0914 in our model
(Fig. 5a), have been observed to give low-level resistance when
mutated in N. gonorrhoeae DNA gyrase12. It is interesting that the
benzisoxazole group of AZD0914 has a vector pointing a pendant
oxazole ring into a similar place as the C7 substituent from
moxiﬂoxacin (Fig. 5b), suggesting that structure–activity
relationships from the highly variable C7 position of
ﬂuoroquinolones could be used to develop new analogues of
QPT-1.
Etoposide is an antibacterial via inhibition of DNA gyrase.
Etoposide’s activity against eukaryotic topo2As has been exten-
sively studied2,28,29 including a structure in complex with human
Top2b7. However, there are few reports on its inhibition of
bacterial enzymes or on its antibacterial activity30,31 and activity
against wild-type bacteria had not been demonstrated to be due to
topoisomerase inhibition. We found that etoposide has activity
against both S. aureus and Escherichia coli topo2As, through the
stabilization of DNA-cleavage complexes, and that etoposide has
dual-targeting activities for gyrase and topo IV (Table 2,
Supplementary Fig. 4 and Supplementary Table 3). In our co-
crystal structures of etoposide with S. aureus gyrase, the central
hydroxyl of the dimethoxy phenol group of etoposide (ring E in
Fig. 1b) interacts with the same main-chain N–H of Asp437 of
GyrB (Fig. 3c) as QPT-1. Hence, etoposide and QPT-1, despite
having very different chemotypes, are nearly isosteric, both
interacting with GyrB Asp437 (Fig. 3a,c small insert panels). The
potency of etoposide for DNA cleavage with S. aureus gyrase was
weaker than that for human Top2a (Table 2), possibly due to the
interaction of the glycosidic moiety of etoposide with Gln778 and
Met782 in the human Top2b structure7. In contrast, in the
S. aureus etoposide structures the equivalent residues, GyrA Ser84
and Glu88, do not make speciﬁc interactions with etoposide
(Fig. 3c). However, mutation of the residue equivalent to Ser84 in
E. coli DNA gyrase can enhance the activity of etoposide against
the bacterial enzymes31,32, showing that a different amino acid at
position 84 of the GyrA subunit of DNA gyrase can make a
favourable interaction with etoposide.
An in vitro gyrase-dependent DNA replication assay9,33 using
toluenized cells from E. coli gave an half-maximal inhibitory
concentration (IC50) of 4.3 mM, showing that inhibition of
bacterial topo2A with etoposide results in functional inhibition
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Figure 5 | A model of AZD0914 in N. gonorrhoeae DNA gyrase. (a)
AZD0914 modelled into a structure of N. gonorrhoeae DNA gyrase (see
Methods for details). Mutations of Lys450 and Asp429 have been found to
give low levels of resistance in laboratory-generated resistant bacteria12.
A mesh molecular surface around the compound (yellow) and Lys450 and
Asp429 (red) are shown. (b) The model of AZD0914 in N. gonorrhoeae
DNA gyrase is shown superposed on the crystal structure of moxiﬂoxacin in
S. aureus DNA gyrase. It is noteworthy that Lys450 (equivalent to Arg458
in S. aureus) and Asp429 (Asp437 in S. aureus) are from two conserved
sequence motifs: PLR/KGK and EGDSA. The blue circle highlights that the
region occupied by the substituent from the C7 position of the
ﬂuoroquinolone (FQ) is also occupied by a substituent in AZD0914.
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of bacterial DNA replication (Table 2). Etoposide demonstrates
potent cytotoxicity to mammalian cells despite modest topo2A
inhibitory action, likely to be due to the generation of highly
lethal ‘poison’ complexes between the enzyme and chromosomal
DNA. Likewise, relatively weak inhibition of bacterial DNA
gyrase results in signiﬁcant in vitro DNA replication inhibition
and whole-cell antibacterial activity (Table 2). Etoposide showed
antibacterial activity against a range of Gram-positive pathogens
and, similar to QPT-1, against efﬂux-deﬁcient mutants of Gram-
negative pathogens (Table 2 and Supplementary Table 4). Among
Gram-positive pathogens, the most notable activity was against
Streptococcus pneumoniae, with antibacterial activity retained
against isogenic mutants harbouring mutations in GyrA/ParC
that confer ﬂuoroquinolone resistance (Supplementary Table 5).
Whereas wild-type Gram-negative pathogens were generally
insensitive to etoposide, their isogenic efﬂux-deﬁcient mutants
were highly sensitive, consistent with increased efﬂux leading to
reduced access of etoposide to the intracellular target
(Supplementary Table 4).
To genetically demonstrate that the antibacterial activity of
etoposide was due to DNA gyrase inhibition, spontaneous
mutants of S. pneumoniae and S. aureus resistant to etoposide
were selected in the laboratory. DNA sequencing of gyrase and
topo IV genes identiﬁed mutations in DNA gyrase, including the
GyrB TOPRIM domain, in resistant mutants from both species
(Table 2 and Supplementary Table 6). To prove that gyrase
mutation was solely responsible for the observed etoposide
resistance, two of the mutations (GyrB D L407–S410 and GyrB
R447C) obtained in S. pneumoniae 1629 were transformed into
S. pneumoniae R6. The resultant transformants contained the
same mutation and were similarly resistant to etoposide as the
original spontaneous mutant. This demonstrates for the ﬁrst time
that etoposide has an antibacterial activity against gyrase
wild-type bacteria that is directly attributable to DNA gyrase
inhibition.
The S. aureus and S. pneumoniae etoposide-resistant mutants
were tested for their susceptibility to a selected range of other
antibacterial and anticancer topo2A inhibitors (Table 3 and
Supplementary Table 6) chosen for structural diversity and
known structural basis of action against human topo2As2,20
(Supplementary Fig.1). The antibacterial spectrum of teniposide,
a podophyllotoxin related to etoposide, was similar to that of
etoposide against wild-type strains (Supplementary Table 4) and
was similarly affected by etoposide-resistant mutants (Table 3 and
Supplementary Table 6). Notable hypersensitivity in certain
etoposide-resistant mutants were observed for mitoxantrone,
amsacrine, daunorubicin, doxorubicin and ellipticine (Table 3
and Supplementary Table 6), suggesting that the antibacterial
activity of these human topo2A inhibitors like etoposide, are due
to gyrase inhibition, but that they do not inhibit the same
conformational state of the enzyme20. The complex variety of
drug resistance and hypersensitivity phenotypes for anticancer
agents observed in the gyrase mutants has also been observed in
eukaryotic topo2A mutants34,35 and mapping the positions of the
resistant mutants onto structures shows that, although some are
footprint mutations7, others are distant from the etoposide-
binding sites.
Structural analysis reveals asymmetric cleavage complexes.
To analyse the different conﬁgurations observed at the DNA gate,
12 of our complexes of S. aureus DNA gyrase with DNA
and 4 unrelated antibacterial compounds, were superposed
(see Methods, Supplementary Figs 7 and 8, and Supplementary
Tables 7 and 8 for details). A comprehensive comparative analysis
revealed a range of conformations with two main clusters con-
taining ﬁve and three structures, respectively, at either end of the
range (Fig. 6g and Supplementary Fig. 7). We named the con-
formation represented by the ﬁrst cluster of ﬁve structures,
CRsym (for cleavage and/or re-ligation-competent symmetrical
conformation, blue structures in Supplementary Fig. 7). These
CRsym structures are BC2 symmetric and include a structure
with the metal ion at the A (or 30)-site9 (Fig. 6c). The presence of
a metal ion (Mg2þ ) at the A (or 30)-site is believed to be
necessary for topo2As, to both cleave and re-ligate the DNA9,36,37
(see Supplementary Discussion). The catalytic CRsym-type
conformation appears to be conserved between eukaryotic and
prokaryotic topo2As (Supplementary Fig. 8). All the CRsym
complexes have either one or no compound bound and have a
larger area buried between the two subunits at the DNA gate
(1,625–1,744Å2) than is observed in the other seven complexes
(Fig. 6g and Supplementary Fig. 7).
The second cluster consists of three asymmetric complexes,
each of which has two compounds bound. We termed this cluster
Casym (for common asymmetrical conformation, red structures
in Supplementary Fig. 7). All three Casym structures (both 2.8 Å
etoposide complexes with two compounds bound and one of the
3.15 Å QPT-1 complexes) have angles between two subunits at
DNA gate of 173.5±0.6 (compared with 179.4–179.9 for
CRsym structures) indicative of a ‘half-open’ conformation at the
DNA gate (Supplementary Table 8). The Casym complexes have
the smallest areas buried (852–897Å2) between the two subunits
at the DNA gate (Fig. 6g and Supplementary Figs 7 and 9). In a
Casym complex, one active site is ‘open’ (Fig. 6a) with relatively
little contact between the two protein subunits, whereas the other
active site (Fig. 6b) is closed and is quite similar to the
conﬁguration seen in a CRsym active conformation (Fig. 6e,f).
Relative to a CRsym structure, the catalytic TyrP in the Casym
etoposide complexes has shifted by 4Å on the ‘open’ half and
only 1.4 Å on the closed half (Fig. 6d–f). To our knowledge, these
Table 3 | Antimicrobial susceptibility to anticancer topo2A inhibitors.
S. aureus strain MIC (lgml1)
Etoposide Teniposide Doxorubicin Daunorubicin Mitoxantrone Amsacrine Ellipticine GSK299423 (NBTI)*
RN4220 parent 64 16 8 8 32 4128 1 0.016
RN4220 GyrB D437Nw 128 32 8 8 32 4128 1 0.125
RN4220 GyrB D437Aw 256 32 8 8 8 32 1 0.125
RN4220 GyrB D437Vw 256 64 8 8 8 64 1 0.125
RN4220 GyrB P456Lw 256 32 4 4 4 32 1 0.125
RN4220 GyrB DT403-K406 256 32 3 1.5 6 128 1 0.016
MIC, minimum inhibitory concentration; topo2A, type IIA topoisomerase.
See Supplementary Table 6 for MIC data to DNA gyrase etoposide-resistant mutants in S. pneumoniae.
MIC values are averages of two independent determinations. Signiﬁcant (Z4-fold) resistance and hypersensitivity are highlighted in bold and italic, respectively.
wMutants isolated with NBTI.
*GSK299423 is a control compound.
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are the ﬁrst asymmetric topo2A DNA-cleavage complexes
reported and show that inhibitors can stabilize an asymmetric
conformation of the DNA gate. The area buried between the
two subunits in the hTOP2b etoposide complex is also small
(565Å2)7 but the DNA gate has cracked open in a different way
in the human etoposide complex (Supplementary Fig. 10e).
The four cleavage complexes (two QPT-1 and two moxiﬂox-
acin complexes) not in the CRsym or Casym clusters have a range
of conﬁgurations (angles between two subunits at DNA gate of
177.5–178.9) intermediate between those of the two clusters.
Furthermore, these intermediate complexes have buried areas
between those observed for the CRsym and Casym clusters
(1,203–1,526Å2, purple structures in Supplementary Fig. 7). The
area buried at a protein:protein interface is sometimes used as a
surrogate for stability38, suggesting that in the absence of
compound the Casym half-open conformation would be the
least stable of the S. aureus DNA gyrase complexes (Fig. 6).
Next, we examined the buried areas of our etoposide structures,
to help explain why we capture cleaved complexes with either one
or two molecules bound, and the observation that etoposide
stabilizes both SSB and DSB (Fig. 2c–f). The CRsym
complex with one etoposide bound has an area of some
1,653Å2 buried between the two gyraseCORE subunits at the
DNA gate (ba_ba’1–etop complex in Fig. 6g). In contrast, the two
‘half-open’ Casym complexes with two etoposides bound
have buried areas of only 877 and 897Å2 (BA_BA’2–etop and
BA_BA’2–etop complexes in Fig. 6g, respectively). This observation
that the DNA gate can close much more fully (and presumably
more stably) with one etoposide bound (Fig. 2d) than with two
etoposides bound (Fig. 2c, see arrow) gives an explanation of why
etoposide gives both SSBs and DSBs with S. aureus DNA gyrase
(Fig. 2f and Supplementary Fig. 4). The two S. aureus gyrase
complexes with two etoposides bound (BA_BA’2–etop and
BA_BA’2–etop) were both in the half-open Casym conformation.
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Figure 6 | Comparison of active sites in asymmetric (Casym) and symmetric (CRsym) S. aureus DNA gyrase complexes. (a,b) Views of the two active
sites in the Casym BA_BA’2–etop etoposide complex (the complex is asymmetric; hence, the two active site are different; this common asymmetric
conformation (Casym) is also seen in the BA_BA’2–etop and BA_BA’2–QPT complexes). The cleaved DNA backbone is shown as a pink (a) or green (b) line.
Surfaces (red and black) are shown on the two protein subunits (catalytic TyrP123 surface not shown for clarity). Etoposides are shown as thin black (a) or
red (b) lines. The scissile phosphates are shown in red and orange sticks forming phosphotyrosine linkages with TyrP123 of GyrA. A metal ion (small purple
sphere) is present at the non-catalytic B site. (c) View of an active site in the CRsym ba_ba’1–NBTI complex9 (the complex is C2 symmetric; hence, the other
active site is the same). The catalytic tyrosine has been mutated to a phenylalanine; thus, the DNA (orange line) is not cleaved. The position of the scissile
phosphate is shown in stick representation for orientation. A metal ion (small black sphere) is present at the catalytic A site. (d) Comparison of a and c
shows a relative shift of 4.0Å between the Ca positions of TyrP/Phe 123. Protein surfaces and etoposide have been removed for clarity. (e) Comparison of b
and c shows a relative shift of 1.4Å between the Ca positions of TyrP/Phe 123. (f) Comparison of a,b and c. (g) Area buried (Å2) between the two protein
subunits at the DNA gate in nine S. aureus B27A56Gkdel complexes with doubly cleaved or doubly nicked DNA (this study) and one S. aureus B27A56Gkdel
complex with uncleaved DNA (ba_ba’1–NBTI)9. Second complexes shown in italics in Table 1 are underlined here for clarity.
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In contrast, S. aureus gyrase complexes with two QPT-1 or two
moxiﬂoxacins molecules bound can have relatively large areas
buried between the two subunits at the DNA gate (1,203–1,526Å2
in Fig. 6g), suggesting that with two QPT-1 or moxiﬂoxacin
molecules the DNA gate can close more completely (more stably)
than with two etoposides bound (this might be because etoposide
is less ﬂat and keeps the 1 and þ 1 bases further apart).
Consistent with the different stabilities of inhibitor complexes
observed at the DNA gate, QPT-1 and moxiﬂoxacin were
more potent than etoposide in DNA gyrase enzyme assays
(Table 2a).
Discussion
The ﬂuoroquinolones are the only class of topoisomerase
inhibitors widely used as antibacterial drugs; however, their
utility is threatened by target-mediated resistance. Our work
reveals the structural basis for inhibition by QPT-1, the
progenitor of an entirely different class of antibacterial14. We
ﬁnd that QPT-1, similar to the ﬂuoroquinolones, binds between
the þ 1 and 1 bases at the DNA-cleavage site, blocking the
approach of the scissile phosphate to the 30-hydroxyl of the
cleaved DNA and thereby inhibiting DNA re-ligation. However,
the QPT-1 binding mode is not identical to ﬂuoroquinolones
(which interact with the GyrA subunit via the magnesium ion
water bridge) and had not been predicted in modelling studies12.
In QPT-1, the barbituric acid moiety sits in a pocket between the
DNA and protein, and interacts with the main-chain N–H of
Asp437 from GyrB; this explains why QPT-1 is active against
ﬂuoroquinolone-resistant strains and suggests ways of developing
new members of this class. Our observations of six QPT-1-related
binding modes (from three QPT-1 cleavage complexes) show
that, although the interaction of QPT-1 with the main-chain N–H
of Asp437 is conserved, the interaction with the G1 base in more
variable (Fig. 4). We propose that QPT-1 can maintain favourable
interactions with slightly different binding pockets because: (i) the
barbituric acid can adopt different keto/enol tautomers and
(ii) the anilino nitrogen of the central ring of QPT-1 can adopt a
more planar sp2 or a more tetrahedral sp3 conformation.
As the barbituric acid is not conﬁned to adopting a
pyrimidinetrione tautomer, we suggest that a better generic
name for the QPT-1 class of antibacterials would be quinoline
barbituric acids.
Hundreds of QPT-1 analogues have been reported in the
literature and patents5,13,39. Our structure rationalizes the
reported structure–activity relationship, in which the barbituric
acid of QPT-1 is essential for antibacterial activity, as this moiety
makes a network of adaptable interactions with GyrB and the
nucleotides on either side of the cleavage site. Modiﬁcations to
this region are not well tolerated and frequently lead to signiﬁcant
decrease of antibacterial activity (in-house unpublished data). The
(þ )-enantiomer of QPT-1 is reported to have greatly reduced
DNA gyrase cleavage activity (B32-fold in Supplementary
Fig. 3c) and antibacterial activity14 compared with the bioactive
() QPT-1 enantiomer. This observed preference can be
explained from our structure, as the dimethyl morpholino
makes interactions with the G1 DNA base (Fig. 3a).
Modelling of AZD0914 into N. gonorrhoeae DNA gyrase based
on our QPT-1 S. aureus gyrase structure rationalizes the
low-level, target-mediated resistance reported for AZD0914
(ref. 12 and Fig. 5). Furthermore, our study reveals the binding
pocket of QPT-1 overlays with moxiﬂoxacin affording opportu-
nities for scaffold hopping. The overlays suggest that the most
variable region between QPT-1 and AZD0914 (Supplementary
Fig. 1) could be replaced with substituents from the highly
variable C7 position of the ﬂuoroquinolones and related
compounds. For example, introducing an aminomethyl pyrolidi-
nyl group at the C7 position has been reported to enhance the
activity of ﬂuoroquinolones40,41; thus, it would be interesting to
determine whether introducing the group at a similar position on
the QPT-1/AZD0914 scaffold can produce more potent
compounds. It might also be interesting to add a siderophore
to a QPT-1 analogue, to see whether cell penetration can be
improved and possibly to try to mimic the ﬂuoroquinolone
water–metal ion bridge6,17,18.
Another promising attribute for antibacterial development of
the quinoline barbituric acid series is their excellent selectivity
towards bacterial targets. QPT-1 does not have detectable activity
against human Top2a (Table 2) and AZD9014 has low activity
against human Top2b42 despite the fact that the amino acids that
QPT-1 contacts are conserved between bacteria and man. To try
to understand the bacterial selectivity of QPT-1, we performed an
extensive analysis of multiple S. aureus DNA gyrase co-crystal
structures (see Methods, Supplementary Figs 7 and 9, and
Supplementary Table 8). This led us to propose a mechanism for
DNA gyrase in which the DNA gate acts like a pair of swing–
doors, in that: (i) it tends to remain closed until the T-DNA is
pushed through43 and (ii) it swings closed immediately after the
passage of the T-DNA (Supplementary Fig. 11 and Supplemen-
tary Discussion). This is consistent with observations of a closed
DNA gate in electron microscopy and small-angle X-ray
scattering (SAXS) studies of DNA gyrase complexes with
DNA44,45. Our ‘swing-doors mechanism’ for DNA gyrase is an
extension of existing ‘standard’ models for topo2A cleavage
mechanisms46,47 but differs in a number of respects (as outlined
below and detailed in Supplementary Discussion). The ‘swing-
doors mechanism’ proposes (see Supplementary Fig. 11) that at
(a) the DNA gate can gently rock to and fro with G-DNA bound,
and that the ﬁrst cleavage step takes place when movement causes
a metal ion (Mg2þ ) to occupy a catalytic ‘A’ site (Supplementary
Fig. 8). In the absence of a captured T-DNA segment, the tension
in the stretched9, now singly cleaved G-DNA is then proposed to
rock the DNA gate, to religate the cleaved DNA strand.
Alternatively, at (b) in the presence of a captured T-DNA
segment, and after the ﬁrst cleavage step, the T-DNA attempts to
push the DNA gate open and the enzyme is moved into the
Casym ‘half-open’ conformation where the second cleavage step
now takes place (the phosphotyrosine from the cleaved strand is
too far away from the metal-binding site for re-ligation to occur
in this ‘half-open’ Casym conformation). Thereafter, at (c) the
ﬁrst re-ligation step is proposed to be catalysed by Lys 581 from
the conserved YKGLG motif41,48, which is moved by the T-DNA
interacting with the Greek Key domain (Supplementary Figs 12
and 13, the T-DNA is between the DNA gate and exit gate at this
stage of the catalytic cycle). It is proposed that this ‘swing-doors’
mechanism for DNA gyrase has evolved to limit, to the minimum
possible, the amount of time that the gate DNA is cleaved
(because both SSBs and DSBs in the DNA can be cytotoxic).
Although there are some DNA-gate conformations that appear
conserved between prokaryotic and eukaryotic topo2As
(Supplementary Fig. 8a–c), the amino acids involved in
protein–protein interactions at the DNA gate of prokaryotic
and eukaryotic topo2As are not highly conserved (Supplementary
Table 7). This lack of sequence conservation seems to be reﬂected
in structural differences, for example, the human Top2b
etoposide structure7 is in a symmetric ‘dropped trap door’37-
like conformation, which we have not observed with gyrase,
whereas the S. aureus gyrase complexes with two etoposides are
in the asymmetric (Casym) conformation (which has not been
observed in eukaryotic topo2A structures).
A structural explanation for QPT-1 selectivity comes from a
comparison of S. aureus QPT-1 and etoposide structures with the
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human Top2b etoposide structure7 (Fig. 7 and Supplementary
Figs 10 and 14). This shows the following: (i) a dramatic
difference in the position of the scissile phosphates linking the
catalytic tyrosine to the cleaved DNA between the human and S.
aureus-binding pockets (Fig. 7, arrowed) and (ii) a small relative
movement of the main-chain N–H of Asp479 of hTop2b
(equivalent to Asp437 of S. aureus GyrB) away from the key
oxygen interaction of QPT-1 (Fig. 7a–c). One outcome of these
observations is that with human htop2b the gap in the binding
pocket between Asp479 /Arg503 and the þ 1 nucleotide (which is
covalently attached to the catalytic tyrosine by the scissile
phosphate) is larger (Fig. 7d versus Fig. 7c), and may be large
enough to allow QPT-1 to exit as the DNA gate closes. Although
QPT-1 interacts with GyrB residues conserved between bacteria
and man, suggesting that bacteria might ﬁnd it difﬁcult to develop
target-mediated drug resistance, laboratory-generated strains of
bacteria with resistance to AZD0914 (ref. 12) have mutated some
of these highly conserved residues (Fig. 5).
In this study we reveal the ﬁrst structure of QPT-1 bound to a
topo2A–DNA complex, the ﬁrst structure of an etoposide-
inhibited complex with a bacterial topoisomerase and the ﬁrst
model of an asymmetric cleavage complex. We also demonstrate
the activity of etoposide and other anticancer agents against
bacteria is due to the inhibition of DNA gyrase. Our co-crystal
structure of a DNA-cleavage complex for QPT-1 reveals QPT-1
binds at the same site in the cleaved DNA as moxiﬂoxacin;
however, unlike the ﬂuoroquinolones, QPT-1 interacts with GyrB
TOPRIM residues. This binding rationalizes why QPT-1 is able to
overcome target-mediated ﬂuoroquinolone resistance. Further-
more, we provide a structural explanation of QPT-1’s bacterial
speciﬁcity by the observed differences in scissile phosphate
positions in human versus bacterial complexes with etoposide.
Collectively, we provide new structural insights and strategies for
discovering new QPT-1 antibacterials that overcome quinolone
resistance, while exploiting knowledge from the ﬂuoroquinolone
class.
Methods
Compounds. QPT-1 was synthesized using published procedures with slight
modiﬁcations and the () and (þ ) enantiomers isolated as described21 in
Supplementary Methods and Supplementary Fig. 16. The bioactive () enantiomer
of QPT-1 was used in all studies, unless stated. Teniposide was purchased from
LKT Labs Inc. Other compounds were obtained from Sigma.
Protein expression and puriﬁcation. The S. aureus fusion truncates used for
crystallography, GyrB27–A56(GKdel) and GyrB27–A56(GKdel/Tyr123Phe), for
simplicity renamed gyraseCORE and gyraseCORE (Y123F), respectively, were
expressed in E. coli BL21 DE3* and puriﬁed in four steps as follows9: (1)
centrifuged cell lysate in lysate buffer (20mM Tris, 1mM EDTA, 2mM
dithiothreitol (DTT), 0.2mM phenylmethylsulfonyl ﬂuoride (PMSF), 1mM
benzamidine, 1mgml1 lysozyme, 1 mgml1 BLAP (a protease inhibitor cocktail
consisting of 1mgml1 each of bestatin, leupeptin, aprotinin and 2mgml1
pepstatin) pH 8.0) was loaded onto a Q Sepharose FF column and washed back to
baseline in Buffer 1A (20mM Tris, 1mM EDTA, 2mM DTT, 0.2mM PMSF, 1mM
benzamidine, 1 mgml1 BLAP pH 8.0), before being eluted with a gradient
from Buffer 1A into Buffer 1B (20mM Tris, 1M NaCl, 1mM EDTA, 2mM DTT,
0.2mM PMSF, 1mM benzamidine, 1 mgml1 BLAP pH 8.0). (2) The puriﬁcation
pool from the ﬁrst step was incubated with an additional 10 ml of benzonase for
30min and then diluted using Buffer 2C (20mM Tris, 1mM EDTA, 2mM DTT
pH 8.0) to reduce the conductivity to B6mScm, before being loaded onto a
Heparin Sepharose column equilibrated in Buffer 2A (20mM Tris, 50mM NaCl,
1mM EDTA, 2mM DTT, 0.2mM PMSF, 1mM benzamidine, 1mgml1 BLAP pH
8.0), and eluted with a gradient into Buffer 2B (20mM Tris, 1M NaCl, 1mM
EDTA, 2mM DTT, 0.2mM PMSF, 1mM benzamidine, 1 mgml1 BLAP pH 8.0)
over eight column volumes. (3) The pooled protein from the Heparin Sepharose
column was diluted into Buffer 2C to reduce the conductivity toB6mScm, before
being loaded onto a 15Q anion exchange column equilibrated in Buffer 2A and
elution with a gradient into 40% Buffer 2B over 12 column volumes. (4) The pooled
fractions from step 3 were concentrated using a YM30 concentrator (yields and
concentrations varied in different preps), before being loaded onto a 320-ml
Superdex 200 column equilibrated and eluted in Buffer 4A (20mM Hepes, 100mM
NaSO4, 5mM MnCl2 pH 7.0). Post size-exclusion fractions were pooled and
concentrated for crystallization. Full-length S. aureus GyrA and GyrB were
expressed in E. coli and puriﬁed as described9.
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Figure 7 | Comparison of a binding site of QPT-1 in S. aureus DNA gyrase with the etoposide-binding site in humanTop2b. (a) The 2.5-Å QPT-1 complex
with S. aureus gyrase (ba_ba2–QPT) is shown superposed on the 2.16-Å etoposide complex with human Top2b (ref. 7) (pdb code: 3qx3). QPT-1 and
etoposide carbons are shown as purple and green balls, respectively. (b) The 2.16-Å etoposide complex with human Top2b. The scissile phosphate is
arrowed. The Aa4 helix shown as a green cylinder. (c) The 2.5-Å QPT-1 complex with S. aureus gyrase. The scissile phosphate is arrowed. It is noteworthy
that QPT-1 does not contact Ser84 or Glu88 from the Aa4 helix (purple cylinder) but forms a key interaction with Asp437 (dotted lines). (d) An illustration
of the human Top2b-binding pocket with QPT-1. The protein and DNA from the S. aureus complex and the etoposide from the human Top2b complex are
not shown. It is noteworthy that the human Top2b pocket seems larger than the pocket in the gyrase complex with QPT-1.
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Gyrase-dependent DNA replication assay. This assay is an indirect method for
measuring target potency of bacterial cells that are undergoing DNA replication
through gyrase-dependent extension of existing replication forks, as determined by
incorporation of 33P-dTTP into DNA33,49. Brieﬂy, E. coli ATCC 25922 was grown
to log phase (OD600 nmB0.6) at 37 C, resuspended in one-tenth volume of cold
0.05M potassium phosphate buffer (pH 7.5) and treated with 1% toluene for
10min at room temperature, to render cells permeable to nucleotide substrates and
cofactors. Toluenized cells were washed in cold buffer and resuspended to 1/25
of the starting volume. DNA gyrase activity was determined by measuring
gyrase-dependent DNA replication in the toluenized cells by the ATP-dependent
incorporation of radiolabelled 33P-TTP. Reactions typically contained at ﬁnal
concentrations per well: 17% v/v toluenized E. coli cells, 0.2 mCi 33P-TTP, 33mM
dATP, 33 mM dGTP, 33mM dCTP, 33mM dTTP, 1.3mM ATP, 70mM KPO4,
2mM DTT and 13mM MgSO4. Reactions were incubated at 37 C for B1 h,
stopped with 10% trichloroacetic acid and Surface Proximity Assay beads added
for scintillation counting.
DNA cleavage assays. S. aureus DNA gyrase cleavage assays were performed
according to published methods9. Brieﬂy, 250 ng of supercoiled pBR322 plasmid
DNA (Topogen) was incubated with either 50 nM of full-length S. aureus DNA
gyrase or 200 nM of S. aureus gyraseCORE protein in 16ml reactions containing
35mM Tris-HCl pH 7.5, 24mM KCl, 4mM MgCl2, 5mM DTT, 360 mgml1 BSA,
6.5% (w/v) glycerol and 1.5mM ATP, in the presence or absence of various
concentrations of inhibitor, at 37 C for 1 h. DNA was released by further
incubation with 0.2% (w/v) SDS and 0.1mgml1 proteinase K at 37 C for 60min.
BlueJuice gel loading buffer (Invitrogen) was added. Samples were analysed by
electrophoresis in 1% w/v agarose gel containing 0.5 mgml1 ethidium bromide
followed by photography under ultraviolet illumination. DNA bands were
quantiﬁed by densitometry using UVP gel imaging software. Values were ﬁtted
by nonlinear regression with GraFit software (Erythacus). CC50, deﬁned as the
concentration of compound needed to generate linear DNA to 50% of the maximal
level, were determined from a minimum of two independent experiments. Each
sample contained compound dissolved in 2% (v/v) dimethylsulfoxide. See
Supplementary Fig. 15 for representative gels.
For DNA-cleavage assays of other topoisomerase enzymes, the same general
procedure was used as described above with modiﬁcations. For S. aureus topo IV
DNA-cleavage reactions, 30 nM of S. aureus topo IV enzyme (Inspiralis) was
incubated with 250 ng supercoiled pBR322 (Inspiralis) in a 20-ml reaction
supplemented with 1.5mM ATP according to vendor’s instructions. For E. coli
DNA gyrase-cleavage assay, 100 nM of E. coli full-length DNA gyrase subunits A
and B (both N-terminally 6-His-tagged) produced in-house (unpublished) were
reconstituted at 30 C for 30min and then incubated with 250 ng supercoiled
pBR322 DNA in a 20-ml reaction containing 35mM Tris pH 7.5, 24mM KCl,
4mM MgCl2, 2mM DTT, 0.1mgml1 albumin, 6.5% glycerol, 1.8mM spermidine
and 1.5mM ATP, and analysed as described9. For E. coli topo IV DNA-cleavage
reaction, 31 nM of E. coli topo IV (Inspiralis) was incubated with 250 ng
supercoiled pBR322 in buffer supplemented with 1mM ATP according to the
manufacturer’s instructions. For human Top2a DNA-cleavage assays, glutathione
S-transferase-tagged human Top2a was produced as described previously50 except
Buffer D was modiﬁed to contain 350mM NaCl and 5% glycerol, and in vitro
cleavage assays performed using 200 nM of the enzyme50.
Topoisomerase inhibition assays. In vitro topoisomerase activity assays were
performed as described with minor modiﬁcations9. Brieﬂy, the supercoiling activity
of S. aureus DNA gyrase was measured in reactions typically containing 3.7 nM of
wild-type S. aureus DNA gyrase, 500 ng relaxed pBR322 plasmid DNA (Inspiralis),
35mM Tris-HCl pH 7.5, 24mM KCl, 700mM potassium glutamate, 4mM MgCl2,
2mM DTT, 1.8mM spermidine, 6.5% (w/v) glycerol, 0.1mgml1 BSA and 1mM
ATP. For E. coli DNA gyrase supercoiling assays, 3.4 nM of wild-type E. coli DNA
gyrase (Inspiralis) was incubated with 500 ng relaxed pBR322 plasmid DNA in a
30-ml reaction containing the same buffer mixture but without the potassium
glutamate. For S. aureus topo IV decatenation assays, 4 nM of S. aureus topo IV
was incubated with 200 ng kinetoplast DNA in buffer as described by the
manufacturer (Inspiralis). In E. coli topo IV decatenation assay, 0.125 nM of E. coli
topo IV was incubated with kDNA as described in the protocol (Inspiralis). Human
Top2a relaxation assays were performed as reported using 2 nM of enzyme50. All
reactions were incubated at 37 C for 1 h and stopped by the addition of BlueJuice
gel loading buffer (Invitrogen). Reactions were analysed by electrophoresis in 1%
w/v agarose gels followed by ethidium bromide staining. IC50 values, deﬁned as the
amount of compound that causes half-maximal inhibition, were determined by
quantifying the DNA products using densitometry (VisionWorks, UVP) and ﬁtting
the data by nonlinear regression with GraFit software (Erythacus). Compound IC50
values reported are the averages of two to three determinations.
Minimum inhibitory concentrations. Antibacterial minimum inhibitory con-
centrations (MICs) were determined from two independent experiments using
broth microdilution methods according to Clinical and Laboratory Standards
Institute guidelines51. The MIC was the lowest concentration of an antibacterial
that showed no visible growth after incubation at 37 C for 18–24 h, with a starting
inoculum of B5.5 105 colony-forming units per ml. Bacterial strains used were
from GSK’s culture collection.
Resistant mutant isolation. Bacterial cells were plated onto Mueller–Hinton agar
plates (for S. aureus RN4220) or Mueller–Hintonþ 5% sheep blood agar plates (for
S. pneumoniae 1629) containing 2 or 4 MIC of etoposide. After 48 h incu-
bation at 37 C, resistant colonies were puriﬁed on etoposide-containing plates and
then on plates without etoposide. The quinolone resistance-determining region
(QRDR) or full-length of gyrA/B and parC/E were ampliﬁed by PCR from the
resistant mutants and DNA sequenced using the following primer pairs (all 50–30
sequence): for S. aureus gyrA: CGTTGTAGAAAACCGTAGACA and GGAAT
TTCAGTGACAACA; gyrB CAAACATGGTGATCCTCA and CGGTCTCATAA
ATCGATAGAAG; parC GTATGCAAGAGGACCAAAGT and CCTTTACCTGA
TTCATAAGCT, and parE CGTGAAGGTTTAACAGCTGTTGTG and CTCTT
CGTCTGTCCAAGC, respectively. For S. pneumoniae gyrA: AGCACCATCACC
GACAAG and ATCCCAACCGCGATACCAG; gyrB: CAAGATTACCAATCGCC
TCTT and CTGCTTCTGCAGCATCATCTA; parC: CTTAAGGGAGCGGTTAA
GAC and TCTTGGAACGAACAACCACG, and parE: AGTAGCCCTCCAGTAC
AATG and ACGTGTTTCTGGGTTCATGG, respectively. S. pneumoniae 1629
genomic DNA harbouring a GyrB L407–S410 deletion or R447C mutation were
transformed into S. pneumoniae R6 strain to regenerate mutants resistant to eto-
poside according to the procedures described52, except AGCH was replaced by
THY (Todd–Hewittþ 0.5% yeast extract) medium. Mutations in etoposide-
resistant transformants were conﬁrmed by PCR and DNA analysis.
Reﬁnement of DNA complexes. The optimization of DNA sequences, crystal-
lization and initial structure determinations of the six complexes are described in
an accompanying paper22.To reﬁne structures, cycles of rebuilding and reﬁnement
were carried out with coot53, Refmac54, Phenix55 and Buster56, to give models with
good geometry (Supplementary Table 1). The Ramachandran plots of the
structures determined had the following percentages of residues in Ramachandran
favoured and Ramachandran outlier regions: (i) 97.7 and 0.15% 2.5Å QPT-1
structure (pdb code 5CDM), (ii) 96.3 and 0.04% 3.15Å QPT-1 structure (pdb code
5CDO), (iii) 97.5% and 0.26% 2.8Å etoposide structure (pdb code 5CDN), (iv) 98.1
and 0.08% 2.45 Å etoposide structure (pdb code 5CDP), (v) 96.7 and 0.64% 2.95Å
moxiﬂoxacin structure (pdb code 5CDQ), and (vi) 97.6 and 0.0% 2.65Å binary
complex (pdb code: 5CDR).
To help determine which QPT-1 tautomer was bound at each of the six QPT-1-
binding sites in the three QPT-1 complexes, the compounds were removed at the
end of reﬁnement and redocked with Aﬁtt57. Aﬁtt has four criteria for evaluating a
docking pose: (i) a real space correlation coefﬁcient for the ﬁt of the pose to the
electron density and (ii) a ligand strain score (the lower the better) and two scores
of the ligand protein interactions (piece-wise linear potential (PLP) and
Chemscore, based only on heavy, non-hydrogen, atom positions). The differences
between the heavy (non-hydrogen) atom positions in the eight possible QPT-1
tautomers are quite small; thus, in docking runs all eight tautomers often gave
similar binding poses in a particular binding site with only small differences in real
space correlation coefﬁcient (typically B0.65–0.68). In Aﬁtt, differences between
neutral QPT-1 tautomers with hydroxyl (O–H) groups on the barbituric acid and
the equivalent unprotonated (O) compound (Supplementary Table 9) were
evident only in the PLP and Chemscore values. The central ring of QPT-1 contains
a nitrogen, which can be either sp2 or sp3—an ‘anilino-type’ nitrogen. The degree of
ligand strain of a particular pose depended, to some extent, on the forceﬁeld used
in the run, either MMff94 (anilino nitrogen restraints sp3) or MMff94s (anilino
nitrogen restraints sp2). Differences in the relative positions of atoms in the
different tautomeric forms of QPT-1 are not large and the resolutions of our S.
aureus gyrase QPT-1 complexes are not high; thus, there is some experimental
uncertainty in the QPT-1 tautomers, which we have tentatively assigned to the
different QPT-1-binding sites (Fig. 4, Supplementary Fig. 6, and Supplementary
Tables 2 and 9). Barbituric acid oxygens, which point towards a delta-negative
region of a p-cloud of a base pair, may be more likely to adopt a protonated (enol
form), whereas if they point towards a delta-positive region of the p-cloud they
may be more likely to adopt the unprotonated (keto form)25. We have not carried
out detailed calculations on the electrostatics of interactions between the different
tautomeric forms of QPT-1 and the surrounding bases.
In the 2.5-Å QPT-1 complex ba_ba’2–QPT, both binding sites appeared to have
the same binding mode and we modelled in tautomer 1 (Fig. 4c, Supplementary
Fig. 6c and Supplementary Tables 2, 9A) with the nitrogen in the central ring
restrained to be sp2 hybridized. The 30-OH of the cleaved DNA is close enough to
donate a hydrogen bond to the side chain of Glu 435’, suggesting that the water
between the 30-OH and the scissile phosphate most probably accepts a hydrogen
bond from an N–H group on the barbituric acid of QPT-1. Docking studies
suggested that one of the QPT-1 molecules in the 3.15Å BA_BA’2–QPT complex
exists with the nitrogen in the central ring in an sp3 conﬁguration, accepting an
internal hydrogen bond from an O–H on the barbituric acid moiety, and we
modelled in tautomer 6 (Fig. 4d, Supplementary Fig. 6c, and Supplementary
Tables 2 and 9C) into this binding site. We modelled tautomer 4 into the other
QPT-1-binding site in the asymmetric BA_BA’2–QPTcomplex and tautomers
5 and 6 into the two binding sites in the BA_BA’2–QPT complex (Fig. 4,
Supplementary Fig. 6c and Supplementary Table 9; all three have the central
ring nitrogen in a planar sp2 conﬁguration; Supplementary Table 2). Two
of the oxygens on the barbituric acid point towards bases in all the QPT-1-binding
sites and interact with p-electrons from the bases. In tautomers 4, 5 and 6
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(Fig. 4, Supplementary Fig.6 and Supplementary Table 2), one or both of the
oxygens pointing at bases have been modelled as hydroxyls (enol rather than
ketone tautomer).
Structural analysis. To analyze the different conﬁgurations observed at the DNA
gate, structures were superposed using Ca atoms from subsets of residues
corresponding to core secondary structural elements from the catalytic TOPRIM
and winged helical domains (residues underlined in Supplementary Fig. 5). The
structures were superposed and root mean square (RMS) ﬁts were calculated with
LSQKAB58. Areas buried between protein subunits at the DNA gate (Fig. 6 and
Supplementary Fig. 9) were calculated with Pisa38 as implemented in Coot and are
‘interface areas’, deﬁned as half-sum of surface area that becomes inaccessible to
solvent when subunits form the interface.
The analysis (Supplementary Fig. 7) showed two clusters of structures: CRsym
and Casym. Five structures formed the CRsym cluster with relatively large areas
buried between the two subunits at the DNA gate (1,625–1,959Å2). In the CRsym
structures the angle between two subunits at the DNA gate is 179.4–179.9
(Supplementary Table 8). The structures in the CRsym cluster have either one or
no compounds bound and are three NBTI (GSK299423) complexes9 with intact
DNA (Y123F mutation), the 2.45-Å etoposide complex with the doubly nicked
DNA and only one compound (ba_ba’1–etop), and a 2.65-Å binary complex with
doubly nicked DNA and no compound (ba_ba’). In the binary complex the four
DNA base pairs stretched9 between the two cleavage sites are not well ordered.
The second cluster Casym contained three asymmetric structures (angle between
two subunits at DNA gate 173.5±0.6) and had the smallest areas buried between
the two subunits at the DNA gate (852–897Å2). The three structures in the Casym
cluster were the two 2.80Å etoposide-cleavage complexes (BA_BA’2–etop and
BA_BA’2–etop) and one of the 3.15-Å QPT-1-cleavage complexes (BA_BA’2–QPT).
The remaining four cleavage complexes, two QPT-1 complexes (ba_ba’2–QPT
and BA_BA’2–QPT) and the two 2.95-Å moxiﬂoxacin-cleavage complexes
(BA_BA’2–moxi and BA_BA’2–moxi), do not form a cluster but have a range
of conﬁgurations intermediate between those of the two clusters and also
have buried areas intermediate between those observed for the two clusters
(1,203–1,526 Å2).These four intermediate structures had angles between domains
at the DNA gate of 177.5–179.9 and RMS ﬁts of 0.732–0.902Å (excluding the two
moxiﬂoxacin complexes, which were quite similar to each other and had an RMS ﬁt
0.282 Å; Supplementary Table 8).
Modelling of AZD0914 in N. gonorrhoeae DNA gyrase. A homology model of
the DNA-cleavage gate of the Gram-negative N. gonorrhoeae DNA gyrase was built
using domains from the crystal structure of the DNA gate of E. coli DNA gyrase
(pdb code: 3NUH59). The domains of N. gonorrhoeae DNA gyrase were
superposed on the equivalent domains in the 2.5 Å S. aureus DNA gyrase complex
with QPT-1. Homology and chemical modelling were carried out in MOE60 and
the structures were minimized using the mmff94 forceﬁeld.
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